EMEA-000380-PIP06-19
Key facts
Invented name |
Cosentyx
|
Active substance |
Secukinumab
|
Therapeutic area |
Immunology-Rheumatology-Transplantation
|
Decision number |
P/0112/2021
|
PIP number |
EMEA-000380-PIP06-19
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of Systemic Lupus Erythematosus (SLE)
|
Route(s) of administration |
Subcutaneous use
|
Contact for public enquiries |
Novartis Europharm Limited
E-mail: paediatric.enquiries@novartis.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|